Takahiro Kogawa

2.1k total citations · 1 hit paper
86 papers, 1.2k citations indexed

About

Takahiro Kogawa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Takahiro Kogawa has authored 86 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Takahiro Kogawa's work include HER2/EGFR in Cancer Research (26 papers), Cancer Treatment and Pharmacology (18 papers) and Breast Cancer Treatment Studies (16 papers). Takahiro Kogawa is often cited by papers focused on HER2/EGFR in Cancer Research (26 papers), Cancer Treatment and Pharmacology (18 papers) and Breast Cancer Treatment Studies (16 papers). Takahiro Kogawa collaborates with scholars based in Japan, United States and United Kingdom. Takahiro Kogawa's co-authors include Naoto T. Ueno, Debu Tripathy, Tamer M. Fouad, James M. Reuben, Bora Lim, Yu Shen, Vicente Valero, Yoichi Naito, Nobuaki Matsubara and Ricardo H. Álvarez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Takahiro Kogawa

72 papers receiving 1.2k citations

Hit Papers

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2... 2024 2026 2025 2024 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
    2024 68 citations Aditya Bardia, Ian E. Krop et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Takahiro Kogawa Japan 19 771 338 334 244 189 86 1.2k
Ernesto Wasserman United States 17 812 1.1× 377 1.1× 418 1.3× 358 1.5× 135 0.7× 35 1.2k
Laura Pizzuti Italy 23 906 1.2× 410 1.2× 454 1.4× 333 1.4× 119 0.6× 96 1.7k
Chiara Pierantoni Italy 16 809 1.0× 245 0.7× 340 1.0× 366 1.5× 145 0.8× 40 1.3k
Shona Nag India 13 720 0.9× 217 0.6× 228 0.7× 228 0.9× 122 0.6× 34 1.0k
Yoshiya Horimoto Japan 20 694 0.9× 378 1.1× 495 1.5× 235 1.0× 66 0.3× 97 1.2k
Jiayi Wu China 20 853 1.1× 656 1.9× 281 0.8× 223 0.9× 147 0.8× 87 1.3k
Teresa Di Desidero Italy 24 542 0.7× 200 0.6× 421 1.3× 253 1.0× 92 0.5× 52 1.1k
Shu Zhao China 21 785 1.0× 409 1.2× 490 1.5× 337 1.4× 67 0.4× 43 1.4k
Alexios Matikas Sweden 19 929 1.2× 413 1.2× 395 1.2× 370 1.5× 69 0.4× 92 1.4k

Countries citing papers authored by Takahiro Kogawa

Since Specialization
Citations

This map shows the geographic impact of Takahiro Kogawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takahiro Kogawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takahiro Kogawa more than expected).

Fields of papers citing papers by Takahiro Kogawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takahiro Kogawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takahiro Kogawa. The network helps show where Takahiro Kogawa may publish in the future.

Co-authorship network of co-authors of Takahiro Kogawa

This figure shows the co-authorship network connecting the top 25 collaborators of Takahiro Kogawa. A scholar is included among the top collaborators of Takahiro Kogawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takahiro Kogawa. Takahiro Kogawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Misawa, Sonoko, Tadamichi Denda, Takuji Suzuki, et al.. (2025). One-year incidence of chemotherapy-induced peripheral neuropathy in oxaliplatin- or taxane-based chemotherapy: a multicenter, prospective registry study (MiroCIP study). Expert Opinion on Pharmacotherapy. 26(3). 335–344. 3 indexed citations
2.
Heist, Rebecca S., Jacob Sands, Aditya Bardia, et al.. (2024). Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treatment Reviews. 125. 102720–102720. 25 indexed citations
3.
Kogawa, Takahiro, Toshinari Yamashita, Takanori Ishida, et al.. (2024). Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.. Journal of Clinical Oncology. 42(16_suppl). 3103–3103. 1 indexed citations
4.
Abe, Tomomi, Akemi Kataoka, Nao Yoshida, et al.. (2024). Desire for pregnancy and fertility preservation in young patients with breast cancer. Breast Cancer. 31(6). 1137–1143. 1 indexed citations
5.
Naito, Yoichi, Seigo Nakamura, Nobuko Kawaguchi‐Sakita, et al.. (2024). Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. 29(11). 1684–1695. 4 indexed citations
6.
Nishizawa, Aya, Koichi Takeda, Tetsuya Urasaki, et al.. (2023). Severe drug eruption after antibiotic administration in patients receiving immune checkpoint inhibitors: A monocentric case series. SHILAP Revista de lepidopterología. 2(2). 330–337.
7.
Naito, Yoichi, Yasutoshi Kuboki, Masafumi Ikeda, et al.. (2021). Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study. Investigational New Drugs. 39(6). 1568–1576. 9 indexed citations
8.
Naito, Yoichi, Chihiro Kondoh, Kenichi Harano, et al.. (2021). The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis. The Breast. 58. 50–56. 6 indexed citations
9.
Doi, Toshihiko, Yutaka Fujiwara, Kohei Shitara, et al.. (2020). The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). Investigational New Drugs. 39(1). 152–162. 10 indexed citations
10.
Tamura, Keita, Shunji Takahashi, Toru Mukohara, et al.. (2020). 346P Phase I study of the liposomal formulation of eribulin (E7389-LF): Results from the HER2-negative breast cancer expansion. Annals of Oncology. 31. S385–S385.
11.
Yamashita, Satoshi, Naoko Hattori, Satoshi Fujii, et al.. (2020). Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy. Scientific Reports. 10(1). 15530–15530. 18 indexed citations
12.
Shimokawa, Mototsugu, Toshinobu Hayashi, Takahiro Kogawa, et al.. (2018). Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy. Anticancer Research. 39(1). 225–230. 8 indexed citations
13.
Fujii, T., Takahiro Kogawa, Wanli Dong, et al.. (2017). Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Annals of Oncology. 28(10). 2420–2428. 110 indexed citations
14.
Lee, Jangsoon, Takahiro Kogawa, Peter Ordentlich, et al.. (2017). Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clinical Cancer Research. 23(16). 4780–4792. 40 indexed citations
15.
16.
Fujii, Takeo, Fanny Le Du, Lianchun Xiao, et al.. (2015). Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer. JAMA Oncology. 1(9). 1311–1311. 69 indexed citations
17.
Abe, Shinji, Yasushi Tsuji, Takahiro Tsushima, et al.. (2010). Efficacy and Feasibility of Combination Chemotherapy with S-1 and Cisplatin (2 Weeks Regimen) for Advanced Gastric Cancer. Japanese Journal of Clinical Oncology. 40(4). 302–306. 2 indexed citations
18.
Sato, Yasushi, Tetsuo Takayama, Daisuke Takahari, et al.. (2008). Successful treatment for gastro-intestinal bleeding of Osler-Weber-Rendu disease by argon plasma coagulation using double-balloon enteroscopy. Endoscopy. 40(S 02). E228–E229. 10 indexed citations
19.
20.
Miyanishi, Koji, Kohichi Takada, Minoru Takahashi, et al.. (2005). A case of huge hepatic hyperplastic nodule located around caudate lobe with enhancement at CT duiring arterial portography. Kanzo. 46(4). 208–214.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ernesto Wasserman Breakdown of academic impact, for papers by Laura Pizzuti Breakdown of academic impact, for papers by Chiara Pierantoni Breakdown of academic impact, for papers by Shona Nag Breakdown of academic impact, for papers by Yoshiya Horimoto Breakdown of academic impact, for papers by Jiayi Wu Breakdown of academic impact, for papers by Teresa Di Desidero Breakdown of academic impact, for papers by Shu Zhao Breakdown of academic impact, for papers by Alexios Matikas
Rankless by CCL
2026